Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.
Selmaj
K W
KW
Department of Neurology, Medical Academy of Lodz, 22 Kopcinskiego Street, 90-153 Lodz, Poland. kselmaj@afazja.am.lodz.pl
D000818:Animals; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000628:therapy; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy; D011092:Polyethylene Glycols / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism / Q000627:therapeutic use; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology*
D018124:Receptors, Tumor Necrosis Factor; D047888:Receptors, Tumor Necrosis Factor, Type I; D053319:Tumor Necrosis Factor Decoy Receptors; D014409:Tumor Necrosis Factor-alpha; C069521:recombinant human tumor necrosis factor-binding protein-1; D011092:Polyethylene Glycols